Healthcare
Regeneron Pharmaceuticals, Inc.(REGN)
Live Price
Offline$609.94
+0.33% today
1Y Change
+19.58%
Window
Jun 23, 2025 โ Jun 12, 2026
- Market Cap
- $72.26B
- Revenue Growth
- +1.0%
- EPS Growth
- +5.3%
- Dividend Yield
- 0.5%
Coverage: 245 bars ยท Jun 23, 2025 โ Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Regeneron Pharmaceuticals, Inc. (REGN) is a Healthcare stock with a market cap of $72.26B and listed on NASDAQ. The stock last traded around $609.94 and up 19.6% across the available one-year price window (Jun 23, 2025 โ Jun 12, 2026). Baseline metrics include revenue growth of +1.0%, EPS growth of +5.3%, a dividend yield of 0.5%. What stands out right now is revenue +1.0%, EPS +5.3%, free cash flow +11.3% with operating margin 24.3% and ROIC 8.5%. The dividend is present but secondary, with a yield around 0.5%. Valuation is more restrained than many high-expectation growth names at P/E 16.5 and price/sales 4.8. Stock Foundry combines REGN price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
+1.0% vs +7.6% peer median
Operating Margin
Above sector median
+24.3% vs +19.4% peer median
P/E
Below sector median
16.5 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Apr 29, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +1.0% and EPS at +5.3%, with operating margin around 24.3%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 0.5%, which matters if the thesis depends on income as much as growth.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +2.3% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Apr 29, 2026 | โ | +3.0% | +5.1% | -9.4% |
2026 Jan 30, 2026 | +6.5% | +1.8% | +5.9% | +6.7% |
2025 Oct 28, 2025 | +22.6% | -0.2% | -4.0% | +20.3% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
REGN
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
REGN Max Drawdown
-26.05%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for REGN and SPY.
Company Overview
Regeneron Pharmaceuticals, Inc.
NASDAQ Global Select
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
- Leadership
- Leonard S. Schleifer
- IPO Date
- Apr 2, 1991
- Employees
- 15.2k
- Street Address
- 777 Old Saw Mill River Road
- Mailing
- Tarrytown, NY, 10591-6707
- Region
- Tarrytown, NY, US
- Reporting Currency
- USD
- Investor Line
- 914 847 7000
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 16.5
- EV/EBITDA
- 12.5
- Price/Sales
- 4.8
- Price/Book
- 2.3
Growth
- Revenue
- +1.0%
- EPS
- +5.3%
- Free Cash Flow
- +11.3%
Profitability
- Gross Margin
- 84.5%
- Operating Margin
- 24.3%
- Net Margin
- 29.6%
- ROE
- 14.3%
- ROIC
- 8.5%
Balance Sheet
- Debt/Equity
- 0.09
- Current Ratio
- 3.57
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.